<DOC>
	<DOCNO>NCT02703714</DOCNO>
	<brief_summary>This open label phase II trial examine efficacy safety novel combination pembrolizumab plus induction GM-CSF patient advance biliary cancer treat UCSF . This phase II study examine efficacy safety novel combination pembrolizumab plus induction GM-CSF advance biliary cancer patient hypotheses combination may increase proportion patient PFS6 compare contemporary historical control , acceptable safety .</brief_summary>
	<brief_title>Pembrolizumab GM-CSF Biliary Cancer</brief_title>
	<detailed_description />
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Be willing able provide write informed consent trial . Have performance status 0 1 ECOG Performance Scale . Demonstrate adequate organ function Patients know hepatitis B C virus ( HBV HCV ) infection eligible provide liver function parameter meet laboratory eligibility criterion Female subject childbearing potential willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study medication Male subject agree use adequate method contraception start first dose study therapy 120 day last dose study therapy . Is currently participate receive study therapy participate receive study therapy study investigational agent , use investigational device within 4 week first dose treatment . Has diagnosis immunodeficiency receive systemic steroid therapy purpose immunosuppression form immunosuppressive therapy within 7 day prior first dose trial treatment . Has know history active TB ( Bacillus Tuberculosis ) . Has know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . Has untreated active Hepatitis B ( e.g. , HBsAg reactive ) . Has active infection require systemic antibiotic therapy time enrollment . Hypersensitivity pembrolizumab excipients . Has receive treatment anticancer monoclonal antibody ( mAb ) within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier . Has receive treatment chemotherapy , target small molecule therapy , radiation therapy nonliver site within 2 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due previously administer agent administer 2 week earlier . Has prior chemoembolization , bland embolization , radioembolization , local ablative therapy , radiation liver tumor , major surgery liver resection within 4 week prior study enrollment recover ( i.e. , ≤ Grade 1 baseline ) adverse event due intervention 4 week earlier . Has know additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin squamous cell carcinoma skin undergone potentially curative therapy situ cervical cancer . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Subjects previously treat brain metastasis may participate provide stable ( without evidence progression image least four week prior first dose trial treatment neurologic symptom return baseline ) , evidence new enlarge brain metastasis , use steroid least 7 day prior trial treatment . Has active autoimmune disease require systemic treatment past 2 year ( i.e . use disease modify agent , corticosteroid immunosuppressive drug ) . Replacement therapy ( e.g. , thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment . Has know history evidence active , noninfectious pneumonitis . Has prior liver organ transplantation . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 agent . Has receive live vaccine within 30 day plan start study therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Advanced</keyword>
	<keyword>Locally-advanced</keyword>
	<keyword>Not eligible resection</keyword>
	<keyword>Prior chemotherapy treatment</keyword>
</DOC>